P3.12D.04

Enhanced vs Standard Dermatologic Management With Amivantamab-Lazertinib in Advanced NSCLC: Phase 2 COCOON Study

Byoung Chul Cho[1], Nicolas Girard[2], Maxwell B Sauder[3], Jill Feldman[4], Weimin Li[5], Farastuk Bozorgmehr[6], Milena Mak[7], Janellen Smith[8], Jairo Simoes[9], Parthiv Mahadevia[9], Bailey G Anderson[9], Tonatiuh Romero[9], Karen Xia[10], George Wang[10], Sean P Murphy[9], Joshua M Bauml[10], Alexander I Spira[11]

[1]Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; [2]Institut du Thorax Curie-Montsouris, Paris, France, and Paris Saclay University, UVSQ, Versailles, France; [3]University of Toronto and Princess Margaret Cancer Centre, Toronto, ON, Canada; [4]EGFR Resisters, Deerfield, IL, USA; [5]West China Hospital of Sichuan University, Chengdu, Sichuan, China; [6]Thoraxklinik Heidelberg gGmbH, University Hospital Heidelberg, Heidelberg, Germany; [7]Instituto do Cancer do Estado de São Paulo – Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil; [8]University of California – Irvine, Irvine, CA, USA; [9]Janssen Research & Development, Raritan, NJ, USA; [10]Janssen Research & Development, Spring House, PA, USA; [11]Virginia Cancer Specialists, Fairfax, VA, USA

Summary

COCOON is a phase 2, open-label, randomized study evaluating the impact of enhanced versus standard dermatologic management in patients with epidermal growth factor receptor (*EGFR*)–mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who were treated with first-line amivantamab + lazertinib

Current Status

The study is currently recruiting, with a goal of 180 patients

Registration Information

This study is registered with ClinicalTrials.gov (Identifier: NCT06120140)

Please scan QR code

Poster

Narrated poster video

https://www.congresshub.com/Oncology/WCLC2024/Amivantamab/Cho

Acknowledgments

We would like to thank the patients who participate in the study and their families and caregivers, the physicians and nurses who care for patients and staff members who support this clinical trial, and the staff members at the study sites and those involved in data collection/analyses. Medical writing assistance was provided by Lumanity Communications Inc. and was funded by Janssen Global Services, LLC.

Disclosures

BCC served in a consulting or advisory role for AstraZeneca, Boehringer Ingelheim, Roche, Bristol Myers Squibb, Pfizer, Yuhan Corporation, Janssen, Takeda, Merck Sharp & Dohme, Ono Pharmaceutical, Eli Lilly, MedPacto, Blueprint Medicines, Cyrus Therapeutics, Guardant Health, Novartis, CJ Bioscience, Abion, BeiGene, CureLogen, Onegene Biotechnology, GI-Cell, HK inno.N, Imnewrun Biosciences Inc, Hanmi, RAND Bioscience, Kanaph Therapeutics, BridgeBio, and Oscotec; served in a leadership role for Interpark Bio and J Ints Bio; holds patents, royalties, or other intellectual property for Champions Oncology, Crown Bioscience, and Imagen; has other relationships with DAAN Biotherapeutics; owns stock or other ownership interests with Theravance, Gencurix, BridgeBio, Kanaph Therapeutics, Cyrus Therapeutics, Interpark Bio, and J Ints Bio; and received research funding from Novartis, Bayer, AstraZeneca, Mogam Biotechnology Research Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan Corporation, Ono Pharmaceutical, Dizal Pharma, Merck Sharp & Dohme, AbbVie, GI Innovation, Eli Lilly, Blueprint Medicines, Interpark Bio, LG Chem, Oscotec, GI-Cell, Abion, Boehringer Ingelheim, CJ Bioscience, CJ Blossom Park, Cyrus Therapeutics, Genexine, Nuvalent Inc, Oncternal Therapeutics, Regeneron, BridgeBio, ImmuneOncia, Illumina, Kanaph Therapeutics, Therapex, J Ints Bio, Hanmi, and CHA Bundang Medical Center.

Background

- Amivantamab is an EGFR-MET bispecific antibody with immune cell–directing activity[1–4]
- Lazertinib is a central nervous system–penetrant, third-generation EGFR–tyrosine kinase inhibitor[5,6]
- In MARIPOSA (ClinicalTrials.gov Identifier: NCT04487080), first-line amivantamab + lazertinib significantly improved progression-free survival versus osimertinib in *EGFR*-mutated advanced NSCLC[7]
- EGFR-targeted therapies are associated with dermatologic adverse events (AEs), which can impact patients' quality of life and treatment adherence, and are often treated reactively with topical/systemic corticosteroids and/or systemic antibiotics[8,9]
- Previous studies have demonstrated that use of a prophylactic oral tetracycline antibiotic resulted in significantly fewer grade ≥2 dermatologic AEs among patients who were receiving EGFR inhibitors[10]

Objectives

- COCOON (ClinicalTrials.gov Identifier: NCT06120140) aims to evaluate the impact of enhanced versus standard dermatologic management on the incidence of dermatologic AEs among patients receiving first-line amivantamab + lazertinib
- Study objectives and endpoints are shown in **Table 1**

Table 1: Study objectives and endpoints

Primary objective	Primary endpoint
• Evaluate the incidence of grade ≥2 DAEIs with enhanced versus standard dermatologic management in patients with locally advanced or metastatic stages IIIB/C to IV *EGFR*-mutated NSCLC who were treated with first-line amivantamab + lazertinib – DAEIs included rash, dermatitis, paronychia, skin fissures, acne, erythema, skin exfoliation, skin lesion, skin irritation, and eczema[a]	• Incidence of grade ≥2 DAEIs in the first 12 weeks after initiation of amivantamab + lazertinib treatment in Arm A versus Arm B[b]
Key secondary objectives	**Key secondary endpoints**
• Characterize dermatologic toxicity in patients who were treated with enhanced versus standard dermatologic management	• Incidence and severity of any DAEIs[b] • Incidence and severity of grade ≥2 DAEIs in the first 6 months[b] • Time to first grade ≥2[b] DAEI • Incidence and severity of paronychia[b] • Incidence and severity of scalp rash[b]
• Assess the impact of enhanced versus standard dermatologic management on patients' health-related quality of life	• Change from baseline ≤12 months in PROs
• Evaluate the impact of enhanced dermatologic management on amivantamab + lazertinib treatment compliance	• Frequency of dose reductions, interruptions, and discontinuations due to DAEIs • Relative dose intensity of amivantamab + lazertinib

[a]Preferred terms included rash, dermatitis acneiform, pruritus, skin fissures, acne, folliculitis, erythema, eczema, maculopapular rash, skin exfoliation, skin lesion, skin irritation, dermatitis, rash erythematous, rash macular, rash papular, rash pruritic, rash pustular, dermatitis contact, dermatitis exfoliative generalized, drug eruption, dyshidrotic eczema, eczema asteatotic, and paronychia.
[b]AE severity per NCI CTCAE v5.0.
AE, adverse event; DAEI, dermatologic adverse event of interest; EGFR, epidermal growth factor receptor; NCI CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events; NSCLC, non-small cell lung cancer; PRO, patient-reported outcome.

Methods

- COCOON is a phase 2, open-label, randomized study currently enrolling patients with treatment-naïve *EGFR*-mutated locally advanced or metastatic NSCLC (**Figure 1**)

Figure 1: Study design



[a]Planned enrollment is 180 patients, which is estimated to provide a power of 90%, with a 2-sided alpha of 0.05, to detect a treatment difference between Arms A and B in the incidence of grade ≥2 dermatologic AEs.
AE, adverse event; APAC, Asia-Pacific; BID, twice daily; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; Ex19del, exon 19 deletion; IV, intravenous; LATAM, Latin America; NSCLC, non-small cell lung cancer; QD, once daily; SPF, sun protection factor.

- As background treatment, all patients will receive intravenous amivantamab + oral lazertinib
  - Prophylactic anticoagulation is mandatory for the first 4 months of treatment
- Patients in Arm A will use a digital health tool to monitor treatment compliance
- All patients will receive general skincare recommendations and will be eligible to receive additional dermatologic measures as per physician discretion
- Additional key inclusion and exclusion criteria are presented in **Table 2**

Table 2: Additional inclusion and exclusion criteria

Inclusion criteria	Exclusion criteria
• ≥18 years of age • Disease is not amenable to curative therapy • May have brain metastases if: all lesions were treated as clinically indicated, any definitive local therapy was completed ≥2 weeks prior to randomization, and patients are receiving no more than prednisone 10 mg (or equivalent) for treatment • Moderate renal impairment (eGFR >45 mL/min) is allowed	• History of uncontrolled illness[a] or significant drug allergy[b] • History of ILD/pneumonitis • History of clinically significant cardiovascular disease[c] • Received any prior systemic treatment at any time for locally advanced stage III or metastatic stage IV disease[d] • Received any prior treatment with an EGFR-TKI for metastatic or unresectable disease[e] • Active or history of leptomeningeal disease • Active hepatitis B or C virus infection or other clinically active liver disease of infectious origin

[a]Including, but not limited to, uncontrolled diabetes, ongoing/active infection, active bleeding diathesis, impaired oxygenation requiring continuous oxygen supplementation, and psychiatric illness or other circumstances that would limit compliance with study requirements.
[b]Known allergy, hypersensitivity, or intolerance to the excipients of amivantamab or lazertinib; to tetracyclines, doxycycline, minocycline, or their excipients; or to any component of the enhanced dermatologic management.
[c]Including, but not limited to, deep vein thrombosis or pulmonary embolism within 1 month prior to administration of the first dose of background anticancer treatment or any of the following within 6 months prior to administration of the first dose: myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary/peripheral artery bypass graft, or any acute coronary syndrome; prolonged QTc interval >480 msec or clinically significant cardiac arrhythmia or electrophysiologic disease; uncontrolled hypertension; congestive heart failure within 6 months of administration of the first dose of study treatment; pericarditis/clinically significant pericardial effusion; left ventricular ejection fraction outside of normal institutional limits during screening; and myocarditis.
[d]Adjuvant/neoadjuvant therapy for stage I/II disease is allowed if administered >12 months prior to the development of locally advanced or metastatic disease.
[e]Adjuvant treatment with osimertinib is allowed if administered >12 months prior to the development of locally advanced or metastatic disease and all osimertinib toxicities are resolved prior to enrollment.
eGFR, estimated glomerular filtration rate; EGFR, epidermal growth factor receptor; Ex19del, exon 19 deletion; FDA, US Food and Drug Administration; ILD, interstitial lung disease; NSCLC, non-small cell lung cancer; QTc, corrected QT interval; TKI, tyrosine kinase inhibitor.

- Patients are being enrolled at 78 sites across 11 countries (**Figure 2**)

Figure 2: COCOON enrollment sites



References

1. Moores SL, et al. *Cancer Res*. 2016;76(13):3942–3953. 2. Vijayaraghavan S, et al. *Mol Cancer Ther*. 2020;19(10):2044–2056. 3. Yun J, et al. *Cancer Discov*. 2020;10(8):1194–1209.
4. Cho BC, et al. *Clin Lung Cancer*. 2023;24(2):89–97. 5. Ahn M-J, et al. *Lancet Oncol*. 2019;20(12):1681–1690. 6. Cho BC, et al. *J Thorac Oncol*. 2022;17(4):558–567.
7. Cho BC, et al. *N Engl J Med*. 2024. doi:10.1056/NEJMoa2403614. 8. Peng Y, et al. *Biosci Trends*. 2019;12(6):537–552. 9. Basse C, et al. *Lung Cancer*. 2022;173:116–123.
10. Petrelli F, et al. *Br J Dermatol*. 2016;175(6):1166–1174.

Corresponding author: Byoung Chul Cho (CBC1971@yuhs.ac)

Lung Cancer

Presented by BC Cho at the World Conference on Lung Cancer (WCLC); September 7–10, 2024; San Diego, CA, USA